Emerson Helps Neste Rapidly Increase Production of Biofuels
Global renewable fuels leader will implement advanced technologies to accelerate its digital transformation and meet…
5 years ago
JFrog Expands Presence in Asia-Pacific, Growing Local Teams in China to Support Increasing Demand for DevOps Solutions
Beijing-based team to accommodate increasing customer demand for hybrid DevOps solutions, building on established activity…
5 years ago
More than 90 Local Enterprises Recognised by GS1 Hong Kong’s Consumer Caring Scheme 2020
70% Consumers Feel More Confident in Consumer Caring Companies HONG KONG SAR - Media…
5 years ago
Wipro, Citrix, Hewlett Packard Enterprise Partner to Accelerate Remote Working Solutions
NEW YORK & BANGALORE, India & SAN JOSE, Calif.--(BUSINESS WIRE)--#COVID19--Wipro Limited (NYSE: WIT, BSE: 507685,…
5 years ago
Plastec Technologies Reports Fiscal 2020 Financial Results
HONG KONG--(BUSINESS WIRE)--Plastec Technologies, Ltd. (OTCBB: PLTYF) (the “Company”) today reported audited financial results for…
5 years ago
Renesas DDR5 I3C Bus Extension and SPD Hub Devices Qualified for AMI Firmware
Expanded I3C Ecosystem Now Includes Firmware, Software, and Hardware, Accelerating Product Qualification and Adoption for…
5 years ago
UMC Files Form 20-F for 2020 with US Securities and Exchange Commission
TAIPEI, Taiwan--(BUSINESS WIRE)--United Microelectronics Corporation (NYSE: UMC; TWSE: 2303) (“UMC”), today filed its 2020 annual…
5 years ago
Almost One-third of Global Pet Care Sales to Come From E-commerce By 2026
LONDON--(BUSINESS WIRE)--#OnlinePetSales--Pet care will continue to benefit from the online retail sales boom during the…
5 years ago
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
- CANbridge to lead development and commercialization in China; expands rare disease pipeline - Mirum…
5 years ago
Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients
Independent data safety monitoring board (DSMB) formally recommends investigational combination therapy advance to Phase 3…
5 years ago